路透社伦敦/哥本哈根10月17日 - 诺和诺德NOVOb.CO在LinkedIn上发表声明称，已任命美国制药业高管格雷格-麦利（Greg Miley）为其新任企业事务主管，因为这家肥胖症制药商在药品定价方面面临着来自特朗普政府越来越大的压力。
美国人麦利目前是美国制药巨头艾伯维公司（AbbVie ABBV.N）负责政府事务的高级副总裁。他周五在LinkedIn上发布了这一声明，诺和诺德公司与路透社分享了这一声明。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.